Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease

Journal of Lipid Research

Volumn 44, Issue 12, 2003, Pages 2374-2381

  Olivieri, Oliviero ^a   Bassi, Antonella ^a   Stranieri, Chiara ^a   Trabetti, Elisabetta ^a   Martinelli, Nicola ^a   Pizzolo, Francesca ^a   Girelli, Domenico ^a   Friso, Simonetta ^a   Pignatti, Pier Franco ^a   Corrocher, Roberto ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

ApoC III; Apolipoproteins; Coronary disease; Genes; Lipids

Indexed keywords

APOLIPOPROTEIN C3; INSULIN; LIPID;

ADULT; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; DISEASE MARKER; DNA POLYMORPHISM; FEMALE; GENOTYPE; HUMAN; INSULIN RESPONSE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL;

ADULT; ALLELES; APOLIPOPROTEIN C-III; APOLIPOPROTEINS C; BIOLOGICAL MARKERS; CORONARY ARTERIOSCLEROSIS; DATA INTERPRETATION, STATISTICAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LIPIDS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; SUBSTRATE SPECIFICITY;

EID: 9144226803     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300253-JLR200     Document Type: Article

References (35)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. 2001. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). J. Am. Med. Assoc. 285: 2846-2497.
2. Isoma, B., P. Almgren, T. Tuomi, B. Forsen, K. Lahti, M. Nissen, M. R. Taskinene, and L. Groop. 2001. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 24: 683-689.
3. Ford, E. S., W. H. Giles, and W. H. Dietz. 2002. Prevalence of the metabolic syndrome among US adults. Findings from the Third National Health and Nutrition Examination Survey. J. Am. Med. Assoc. 287: 356-359.
4. Zimmet, P., E. J. Boyko, G. R. Collier, and M. de Courten. 1999. Etiology of the metabolic syndrome: potential role of insulin resistance, leptin resistance, and other players. Ann. N. Y. Acad. Sci. 892: 25-44.
5. Groop, L., and M. Orho-Melander. 2001. The dysmetabolic syndrome. J. Intern. Med. 250: 105-120.
6. Hulthe, J., L. Bokemark, J. Wikstrand, and B. Fagerberg. 2000. The metabolic syndrome, LDL particle size, and atherosclerosis. The Atherosclerosis and Insulin Resistance (AIR) Study. Arterioscler. Thromb. Vasc. Biol. 20: 2140-2147.
7. Bard, J. M., M. A. Charles, I. Juhan-Vague, P. Vague, P. Andrè, M. Safar, J. C. Fruchart, and E. Eschwege, on behalf of the BIGPRO Study Group. 2001. Accumulation of triglyceride-rich lipoprotein in subjects with abdominal obesity, (BIGPRO) 1 study. Arterioscler. Thromb. Vasc. Biol. 21: 407-414.
8. Chan, D. C., G. F. Watts, P. H. Barett, J. C. L. Mamo, and T. G. Redgrave. 2002. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin. Chem. 48: 278-283.
9. McConathy, W. J., J. C. Gesquiere, H. Bass, A. Tartar, J. C. Fruchart, and C. S. Wang. 1992. Inhibition of lipoprotein lipase activity by synthetic peptides of apolipoprotein C-III. J. Lipid Res. 33: 995-1003.
10. Ginsberg, H. N., N. A. Le, I. J. Goldberg, J. C. Gibson, A. Rubinstein, P. Wang-Iverson, N. Norum, and W. V. Brown. 1986. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and Al. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo. J. Clin. Invest. 78: 1287-1295.
11. Jong, M. C., M. H. Hofker, and L. M. Havekes. 1999. Role of apoCs in lipoprotein metabolism. Functional differences between apoCI, apoC2, and apoC3. Arterioscler. Thromb. Vasc. Biol. 19: 472-484.
12. Blankenhorn, D. H., P. Alaupovic, E. Wickham, H. P. Chin, and S. P. Azen. 1990. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Circulation. 81: 470-476.
13. Hodis, H. N., W. J. Mack, S. P. Azen, P. Alaupovic, J. M. Pogoda, L. La Bree, L. C. Hemphill, D. M. Kramsch, and D. H. Blankenhorn. 1994. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiographyl in a controlled trial of lovastatin. Circulation. 90: 42-49.
14. Mack, W. J., R. M. Krauss, and H. N. Hodis. 1996. Lipoprotein subclasses in the monitored atherosclerosis regression study (MARS). Treatment effects and relation to coronary angiographic progression. Arterioscler. Thromb. Vasc. Biol. 16: 697-704.
15. Luc, G., C. Fievet, D. Arveiler, A. E. Evans, J. M. Bard, F. Cambien, J. C. Fruchart, and P. Ducimetiere. 1996. Apolipoproteins C-III and E in apo B- and non-apo B-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. J. Lipid Res. 37: 508-517.
16. Thompson, G. R. 1998. Angiographic evidence for the role of triglyceride-rich lipoproteins in progression of coronary artery disease. Eur. Heart J. 19: H31-H36.
17. Sacks, F. M., P. Alaupovic, L. A. Moye, T. G. Cole, B. Sussex, M. J. Stampfer, M. J. Pfeffer, and E. Braunwald. 2000. VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial. Circulation. 102: 1886-1892.
18. Chen, M., J. L. Breslow, W. Li, and T. Leff. 1994. Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels. J. Lipid Res. 35: 1918-1924.
19. Dammeman, M., L. A. Sandkuijl, J. L. Halaas, W. Chung, and J. L. Breslow. 1993. An apolipoprotein CIII haplotype protective against hypertriglyceridemia is specified by promoter and 3′ untranslated region polymorphisms. Proc. Natl. Acad. Sci. USA. 90: 4562-4566.
20. Li, W. W., M. Dammeman, J. D. Smith, S. Metzger, J. L. Breslow, and T. Leff. 1995. Common genetic variation in the promoter of the human apoCIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J. Clin. Invest. 96: 2601-2605.
21. Olivieri, O., C. Stranieri, A. Bassi, B. Zaia, D. Girelli, F. Pizzolo, E. Trabetti, S. Cheng, M. A. Grow, P. F. Pignatti, and R. Corrocher. 2002. Apolipoprotein CIII gene polymorphisms and risk of coronary artery disease. J. Lipid Res. 43: 1450-1457.
22. Matthews, D. R., J. P. Hosker, A. S. Rudenski, G. A. Naylor, D. F. Treacher, and R. L. Turner. 1985. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28: 412-419.
23. Tilly, P., C. Sass, M. Vincent-Viry, D. Aguillon, G. Siest, and S. Visvikis. 2003. Biological and genetic determinants of serum apoC-III concentration: reference limits from the Stanislas cohort. J. Lipid Res. 44: 430-436.
24. Pennacchio, L. A., M. Olivier, J. A. Hubacek, J. C. Cohen, D. R. Cox, J-C. Fruchart, R. M. Krauss, and E. M. Rubin, 2001. An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing. Science. 294: 169-173.
25. Talmud, P. J., E. Hawe, S. Martin, M. Olivier, G. J. Miller, E. M. Rubin, L. A. Pennacchio, and S. E. Humphries. 2002. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum. Mol. Genet. 11: 3039-3046.
26. Wong, W. M., E. Hawe, L. K. Li, G. J. Miller, V. Nicaud, L. A. Pennacchio, S. E. Humphries, and P. J. Talmud. 2003. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ. Res. 92: 969-975.
27. Chan, D. C., G. F. Watts, T. G. Redgrave, T. A. Mori, and P. H. Barrett. 2002. Apolipoprotein B-100 kinetics in visceral obesity: associations with plasma apolipoprotein C-III concentration. Metabolism. 51: 1041-1046.
28. Gervaise, N., M. A. Garrigue, G. Lasfargue, G. and P. Lecomte. 2000. Triglycerides, apoC3 and Lp B:C3 and cardiovascular risk in type II diabetes. Diabetologia. 43: 703-708.
29. Attia, N., D. Vincent, M. Cambilleau, D. Roche, and A. Girard-Globa. 2000. Postprandial concentrations and distribution of apoC-III in type 2 diabetic patients. Effect of bezafibrate treatment. Atherosclerosis. 149: 427-433.
30. Surguchov, A. P., G. P. Page, L. Smith, W. Patsch, and E. Boerwinkle. 1996. Polymorphic markers in apolipoprotein C-III gene flanking regions and hypertriglyceridemia. Arterioscler Thromb. Vasc. Biol. 16: 941-947.
31. Hegele, R. A., P. W. Connelly, A. J. G. Hanley, F. Sun, S. B. Harris, and B. Zinman. 1997. Common genomic variation in the APOC3 promoter associated with variation in plasma lipoproteins. Arterioscler. Thromb. Vasc. Biol. 17: 2753-2758.
32. Shoulders, C. C., T. T. Grantham, J. D. North, A. Gaspardone, E Tomai, A. de Fazio, F. Versaci, P. A. Gioffre, and N. J. Cox. 1996. Hypertriglyceridemia and the apolipoprotein CIII gene locus: lack of association with the variant insulin response element in Italian school children. Hum. Genet. 98: 557-566.
33. Jamshidi, Y., D. M. Flavell, E. Hawe, P. K. MacCallum, T. W. Meade, and S. E. Humphries. 2002. Genetic determinants of the response to bezafibrate treatment in the Lower Extremity Arterial Disease Event Reduction (LEADER) trial. Atherosclerosis. 163: 183-192.
34. Grundy, S. M. 2002. Obesity metabolic syndrome, and coronary atherosclerosis. Circulation. 105: 2696-2698.
35. Ginsberg, H. N. 2000. Insulin resistance and cardiovascular disease. J. Clin. Invest. 106: 453-458.